Pinned Tweet
I’ve been quiet on social media lately, but today I’m launching Audit Clinical Evidence (ACE), an initiative I’ve been developing over the past year.
ACE documents errors, inconsistencies, and potential research misconduct, including falsification, in clinical and medical research. Our audit reports are evidence-based and openly available, with supporting analyses and materials shared for transparency and independent scrutiny.
We use the ACE Research Integrity Violations (ACE-RIV) taxonomy to classify and document these issues systematically and consistently.
Many more posts to come!
Take a look: AuditClinicalEvidence.org
Matthew B. Jané retweeted
I relocated my artifact and effect size simulator on my website and added new visualizations and features. It now includes odds ratios and risk ratios!
Check it out: matthewbjane.com/artifact-si…
I relocated my artifact and effect size simulator on my website and added new visualizations and features. It now includes odds ratios and risk ratios!
Check it out: matthewbjane.com/artifact-si…
Matthew B. Jané retweeted
New ACE audit report: Singh et al. (1997), one of the most cited trials of resistance training for depression in older adults.
Misreporting of standard deviations and impossible statistics led many meta-analyses to artificially inflated effects. The largest effect a correct extraction can produce is −0.72. Yet the median effect meta-analyses assign to Singh is −2.74!! Why is that? 1/3
auditclinicalevidence.org/re…
New ACE audit report: Singh et al. (1997), one of the most cited trials of resistance training for depression in older adults.
Misreporting of standard deviations and impossible statistics led many meta-analyses to artificially inflated effects. The largest effect a correct extraction can produce is −0.72. Yet the median effect meta-analyses assign to Singh is −2.74!! Why is that? 1/3
auditclinicalevidence.org/re…
A mean of 13.6 is reported for 4 people, impossible because 4 whole-number scores average to quarters (13.5 or 13.75). Training intensity has an SD of 24 within a 45–87% range, more than the range allows. Many p-values can't be reproduced either. 24 impossible statistics in all.
check out the full report: auditclinicalevidence.org/re…
Matthew B. Jané retweeted
If you're looking for concrete examples of 'evidence contamination', you should definitely take a look at this forensic analysis of three highly-cited (and heavily problematic) papers on exercise for depression:
auditclinicalevidence.org/re…
Brilliant work by @MatthewBJane
Matthew B. Jané retweeted
The Audit Clinical Evidence (ACE) Initiative posted an update to the first audit report (wrt Abdelbasset et al 2019). Gideon Meyerowitz-Katz found some additional errors in the baseline tables that have now been included in the report.
Some additional things:
- Version control through Zenodo is fully set up. Each report has a change log and a DOI for each version.
- New cover pages and some new aesthetic changes to the PDF versions of the audit reports.
- Thanks Gideon Meyerowitz-Katz for posting the report on pubpeer!
I will make a separate post summarizing the findings for this report.
auditclinicalevidence.org/re…
The Audit Clinical Evidence (ACE) Initiative posted an update to the first audit report (wrt Abdelbasset et al 2019). Gideon Meyerowitz-Katz found some additional errors in the baseline tables that have now been included in the report.
Some additional things:
- Version control through Zenodo is fully set up. Each report has a change log and a DOI for each version.
- New cover pages and some new aesthetic changes to the PDF versions of the audit reports.
- Thanks Gideon Meyerowitz-Katz for posting the report on pubpeer!
I will make a separate post summarizing the findings for this report.
auditclinicalevidence.org/re…
How Do We Deal With Seriously Problematic Research? via @GidMK . Let's look at @MatthewBJane 's work
gidmk.substack.com/p/how-do-…
Matthew B. Jané retweeted
I’ve been quiet on social media lately, but today I’m launching Audit Clinical Evidence (ACE), an initiative I’ve been developing over the past year.
ACE documents errors, inconsistencies, and potential research misconduct, including falsification, in clinical and medical research. Our audit reports are evidence-based and openly available, with supporting analyses and materials shared for transparency and independent scrutiny.
We use the ACE Research Integrity Violations (ACE-RIV) taxonomy to classify and document these issues systematically and consistently.
Many more posts to come!
Take a look: AuditClinicalEvidence.org
Matthew B. Jané retweeted
In March 2024, at the age of 35, I was diagnosed with stage IV rectal cancer with a metastasis in my liver. This was a shock: I had no family history, and none of the doctors suspected it. After two years of chemotherapy, radiation, and multiple surgeries, I'm still not cured. Now I'm asking for help to get a personalized cancer vaccine.
This is my story so far.
Following diagnosis, I was treated with total neoadjuvant therapy at UCLA. I had 6 weeks of radiation and chemotherapy (Xeloda). This was followed by 6 rounds of oxaliplatin infusions and Xeloda. I tolerated this unusually well. During this period, I managed to hike up to over 11,000ft multiple times in the Sierras, and I wrote the main text of a 72 author meta-analysis paper and submitted it to Nature where it is still in review.
I showed a good clinical response, and at the end of October I had surgery: I was under for 9 hours, and they cut out a bit of my rectum, 1/3rd of my liver, and gave me a temporary ileostomy. Waking up from this was probably the strangest experience of my life: I felt more machine than man, and I had wild hallucinations form such a large dose of anesthesia.
It took a while to feel OK after that surgery. However, I still had the ostomy. I had that reversed at the end of January in another surgery, which took a greater toll on me than I expected.
I only just started to feel OK again and I got bad news: I got a positive circulating tumor DNA test (ctDNA), the signatera test from natera. Unfortunately, the ctDNA carried on rising, and in July 2025 a new lesion appeared in a lymph node near my liver (periportal).
I was treated with irinotecan and panitumumab infusions, which showed a good response, followed by live MRI guided SBRT radiation treatment to the lesion. However, after finishing this treatment, the ctDNA remained positive and began rising again. I restarted irinotecan and panitumumab infusions, which brought ctDNA back to negative (signatera), although it remained positive on the more sensitive Personalis assay.
During this period I had begun to develop stomach pain and digestive symptoms. Then I collapsed vomiting blood while out in Santa Monica and was rushed to the ER. They found out I had a duodenal ulcer that had bled. I had some blood transfused, and I was sent home to complete an intensive course of antibiotics for H. Pylori infection.
However, after about a week, I started to get very weak. I collapsed again and went back to the ER in an ambulance. They found my hemoglobin was 5g/dL, a dangerously low level (normal is over 13.5). Multiple blood transfusions didn't bring it up and I collapsed again in the night after passing a large amount of blood. They took me to intensive care and performed an emergency endoscopy where they clipped and sprayed the ulcer. Thankfully this worked and I was discharged after another 3 nights in hospital.
Unsurprisingly, nearly bleeding to death wasn't good for me, and my ctDNA began to spike rapidly. I had a PET-CT and it revealed 3 new disease sites in abdominal lymph nodes. I restarted irinotecan and panitumumab infusions after barely recovering from the ulcer incident. This showed an excellent response, with the sites resolving on imaging, although ctDNA remained positive.
I've now started bot/bal immunotherapy, a not yet approved immunotherapy treatment that is the first of its kind to show strong results in my kind of cancer, micro-satellite stable colorectal cancer. This was possible thanks to a donation from an anonymous benefactor and supporter of free and open inquiry in science.
Hopefully this treatment will be effective, but it is unlikely to be enough on its own to prevent future disease recurrence.
I am asking for help to get a personalized neoantigen cancer vaccine, which could substantially increase my chances of surviving this deadly disease that is likely incurable under standard care.
While cancer vaccines have shown promising results, they are not yet approved, meaning one has to pay for the design, manufacture, and administration of the vaccine. The total cost of which is $104,133, beyond my means or those of my family.
Any help would be greatly appreciated! I've started a GoFundMe here: gofundme.com/f/cancer-vaccin…. Please donate and share with anyone who might be interested in helping.
I've carried on working throughout this period and I'm still running a research group in statistical genetics at UCLA. I'm hoping to continue making contributions to science for as long as I can, hopefully longer with your help.
Matthew B. Jané retweeted
Is science self-correcting? Not in this Elsevier journal.
Two 'five-second-retractions' were never retracted, even though I reported them to the journal in 2015.
Eleven years later.... nothing.
My latest blog post: scienceintegritydigest.com/2…
Matthew B. Jané retweeted
HBS' latest filing in the Gino lawsuit contains a few new details:
1. A committee of 26 professors, admins, and fellows reviewed the allegations, and *unanimously concluded* that there was *clear and convincing evidence* of research misconduct.
Matthew B. Jané retweeted
It is not a good sign of a journal's commitment to #ResearchIntegrity if it blocks a person who raised concerns in its articles.
@Oncotarget
@OncotargetJrnl
#ImageForensics #ScienceIntegrity
Matthew B. Jané retweeted
Lol Gino is so cooked.
Turns out fabricating data is harder when people have a copy of all the files on your computer.
Matthew B. Jané retweeted
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer
Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived
#ASCO26

















